0MGB Stock Chart & Stats
kr1804.16
kr20.29(1.27%)
At close: 4:00 PM EST
kr1804.16
kr20.29(1.27%)
Day’s Range― - ―
52-Week Rangekr1,337.00 - kr2,256.00
Previous CloseN/A
Volume5.49K
Average Volume (3M)22.10K
Market Cap
kr113.67B
Enterprise Valuekr63.39B
Total Cash (Recent Filing)kr3.23B
Total Debt (Recent Filing)kr143.00M
Price to Earnings (P/E)21.4
Beta0.94
Next Earnings
Aug 06, 2026EPS Estimate
22.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)105.36
Shares Outstanding62,353,252
10 Day Avg. Volume15,262
30 Day Avg. Volume22,097
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr2,407.14Price Target Upside33.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
0MGB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest share price was kr1337.00 and its highest was kr2256.00 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is kr113.67B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Aug 06, 2026 which is in 22 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on May 07, 2026. The company reported kr5.425 earnings per share for the quarter, missing the consensus estimate of kr10.176 by -kr4.751.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 22.52.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 62,353,252 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of kr5.425 in its last earnings report, missing expectations of kr10.176. Following the earnings report the stock price went up 0.845%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GB:0MGB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genmab A/S
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
0MGB Stock 12 Month Forecast
Average Price Target
kr2,407.14
▲(33.42% Upside)